blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2932982

EP2932982 - A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.08.2019
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  31.08.2018
FormerGrant of patent is intended
Status updated on  11.04.2018
FormerExamination is in progress
Status updated on  25.11.2016
Most recent event   Tooltip09.07.2021Lapse of the patent in a contracting state
New state(s): HU		published on 11.08.2021  [2021/32]
Applicant(s)For all designated states
Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury, NJ 08512 / US
[2015/43]
Inventor(s)01 / Mugrage, Benjamin
1 Cedar Brook Drive
Cranbury, NJ 08512 / US
 [2015/43]
Representative(s)Miller Sturt Kenyon
9 John Street
London WC1N 2ES / GB
[2015/43]
Application number, filing date15153174.617.05.2006
[2015/43]
Priority number, dateUS20050682241P17.05.2005         Original published format: US 682241 P
US20050729329P21.10.2005         Original published format: US 729329 P
[2015/43]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP2932982
Date:21.10.2015
Language:EN
[2015/43]
Type: B1 Patent specification 
No.:EP2932982
Date:03.10.2018
Language:EN
[2018/40]
Search report(s)(Supplementary) European search report - dispatched on:EP16.07.2015
ClassificationIPC:A61K48/00
[2015/43]
CPC:
A61K31/445 (EP,KR,US); A61K31/44 (US); A61K31/4525 (EP,US);
A61K31/4545 (EP,US); A61K38/47 (EP,US); A61K9/20 (KR);
A61P1/16 (EP); A61P11/04 (EP); A61P21/00 (EP);
A61P25/18 (EP); A61P3/00 (EP,US); A61P43/00 (EP);
A61P9/04 (EP); C07D211/46 (EP,US); C07D405/06 (EP,US);
C07D409/06 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2015/43]
TitleGerman:Verfahren zur Behandlung der Pompe-Krankheit mit 1-desoxynojirimycin und Derivaten[2015/43]
English:A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives[2015/43]
French:Procédé pour le traitement de la maladie de Pompe au moyen de 1-désoxynojirimycine et de ses dérivés[2015/43]
Examination procedure27.02.2015Examination requested  [2015/43]
21.04.2016Amendment by applicant (claims and/or description)
23.11.2016Despatch of a communication from the examining division (Time limit: M04)
24.03.2017Reply to a communication from the examining division
09.08.2017Despatch of a communication from the examining division (Time limit: M02)
16.10.2017Reply to a communication from the examining division
12.04.2018Communication of intention to grant the patent
14.08.2018Receipt of the translation of the claim(s)
22.08.2018Fee for grant paid
22.08.2018Fee for publishing/printing paid
Parent application(s)   TooltipEP06770637.4  / EP1896083
Divisional application(s)EP18190283.4  / EP3441090
EP20177473.4  / EP3782655
Opposition(s)04.07.2019No opposition filed within time limit [2019/37]
Fees paidRenewal fee
27.02.2015Renewal fee patent year 03
27.02.2015Renewal fee patent year 04
27.02.2015Renewal fee patent year 05
27.02.2015Renewal fee patent year 06
27.02.2015Renewal fee patent year 07
27.02.2015Renewal fee patent year 08
27.02.2015Renewal fee patent year 09
12.05.2015Renewal fee patent year 10
10.05.2016Renewal fee patent year 11
10.05.2017Renewal fee patent year 12
11.05.2018Renewal fee patent year 13
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU17.05.2006
AT03.10.2018
CY03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
IE17.05.2019
LU17.05.2019
BE31.05.2019
CH31.05.2019
LI31.05.2019
[2021/32]
Former [2021/26]AT03.10.2018
CY03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
IE17.05.2019
LU17.05.2019
BE31.05.2019
CH31.05.2019
LI31.05.2019
Former [2020/26]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
IE17.05.2019
LU17.05.2019
BE31.05.2019
CH31.05.2019
LI31.05.2019
Former [2020/21]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
IE17.05.2019
LU17.05.2019
CH31.05.2019
LI31.05.2019
Former [2020/17]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
TR03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
LU17.05.2019
CH31.05.2019
LI31.05.2019
Former [2020/11]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
LU17.05.2019
CH31.05.2019
LI31.05.2019
Former [2020/07]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
MC03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/50]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
SE03.10.2018
SI03.10.2018
SK03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/40]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
SE03.10.2018
SK03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/37]AT03.10.2018
CZ03.10.2018
DK03.10.2018
EE03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
RO03.10.2018
SE03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/34]AT03.10.2018
CZ03.10.2018
DK03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
SE03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/26]AT03.10.2018
CZ03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
SE03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
PT03.02.2019
Former [2019/24]AT03.10.2018
CZ03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
SE03.10.2018
BG03.01.2019
GR04.01.2019
IS03.02.2019
Former [2019/23]AT03.10.2018
CZ03.10.2018
FI03.10.2018
LT03.10.2018
LV03.10.2018
NL03.10.2018
PL03.10.2018
BG03.01.2019
IS03.02.2019
Former [2019/22]CZ03.10.2018
FI03.10.2018
LT03.10.2018
NL03.10.2018
PL03.10.2018
BG03.01.2019
IS03.02.2019
Former [2019/21]FI03.10.2018
LT03.10.2018
NL03.10.2018
IS03.02.2019
Former [2019/20]LT03.10.2018
NL03.10.2018
Former [2019/17]NL03.10.2018
Documents cited:Search[Y] WO2004069190  (SINAI SCHOOL MEDICINE et al.)
 [Y] US6583158  (FAN JIAN-QIANG et al.)
 [Y] WO0197829  (GENZYME CORP et al.)
 [A] US2004204379  (CHENG SENG H et al.)
 [A]   MELLOR H R ET AL: "Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis", BIOCHEMICAL JOURNAL, vol. 381, no. Part 3, 1 August 2004 (2004-08-01), pages 861 - 866, XP002541351, ISSN: 0264-6021
 [AP]   PARENTI G ET AL: "Alpha-glucosidase enhancement in fibroblasts from patients with Pompe disease", JOURNAL OF INHERITED METABOLIC DISEASE, KLUWER ACADEMIC PUBLISHERS, DO, vol. 28, no. suppl.1, 1 July 2005 (2005-07-01), Abstracts - SSIEM 42st Annual Symposium, Paris, France, 6-9 September, 2005, pages 193, XP002541352, ISSN: 1573-2665
 [AP]   BUTTERS T D ET AL: "Imino Sugar Inhibitors for Treating the lysosomal Glycosphingolipidoses", GLYCOBIOLOGY, OXFORD UNIVERSITY PRESS, US, vol. 15, no. 10, 1 October 2005 (2005-10-01), pages 43R - 52R, XP008124586, ISSN: 0959-6658, [retrieved on 20050518], DOI: 10.1093/GLYCOB/CWI076

DOI:   http://dx.doi.org/10.1093/GLYCOB/CWI076
by applicantUS6537785
 US5798366
 US6291657
 US6660749
 US6274597
 US6583158
 US6589964
 US6599919
 US6916829
 US98842804
 US98842704
 US5900360
 US6270954
 US6541195
 US4806650
 EP0049858
 WO2005063706
 US4639436
 WO2004037373
 WO9522975
 US5399567
 US5310745
 WO0056713
 US4880917
 EP0315017
 US5051407
 US4266025
 US5695969
 US4246345
 US430307
 US4407957
 US5798113
 US5654007
 US5780014
 US5814607
 US5879327
 US5520639
 US5846233
 US5704911
 US5580757
 US6395884
 US6458574
 US6461609
 US6210666
 US6083725
 US6451600
 US5236838
 US5879680
 US6188045
 US9721496
 US5672344
 US5139941
 US5252479
 US5753500
 WO9709441
 US5670488
 US6244113
 US6200812
 US4980286
 US5635493
 WO9206180
 WO9222635
 WO9220316
 WO9314188
 US5939401
 US6331524
 US5283185
 US5767099
 WO9309222
   BEUTLER ET AL.: "The Metabolic and Molecular Bases of Inherited Disease, 8th ed", 2001, MCGRAW-HILL, pages: 3635 - 3668
   SCRIVER, C. R., BEAUDET, A. L., SLY, W. S. AND VALLE, D.,: "The Metabolic and Molecular Bases oflnherited Disease", 1995, MCGRAW-HILL, pages: 2529 - 2561
   WEISMANN ET AL., SCIENCE, vol. 169, 1970, pages 72 - 74
   SCRIVER ET AL.: "The Metabolic and Molecular Bases of Inherited Disease 8th ed.", 2001, MCGRAW-HILL, pages: 3589 - 3610
   KLINGE ET AL., NEUROPEDIATRICS, vol. 36, no. 1, 2005, pages 6 - 11
   RABEN ET AL., MOL THER., vol. 11, no. 1, 2005, pages 48 - 56
   ISHII ET AL., BIOCHEM. BIOPHYS. RES. COMM., vol. 220, 1996, pages 812 - 815
   FAN ET AL., NATURE MED, vol. 5, 1999, pages 112 - 115
   MONTALVO ET AL., MOL GENET METAB., vol. 81, no. 3, 2004, pages 203 - 8
   HERMANS ET AL., HUMAN MUTATION, vol. 23, 2004, pages 47 - 56
   WELCH ET AL., CELL STRESS AND CHAPERONES, vol. 1, no. 2, 1996, pages 109 - 115
   WELCH ET AL., JOURNAL OF BIOENERGETICS AND BIOMEN7BRANES, vol. 29, no. 5, 1997, pages 491 - 502
   HERMANS ET AL., J BIOL. CHEM., vol. 266, 1991, pages 13507 - 12
   LIN ET AL., ZHONGHUA MIN GUO XIAO ER KE YI XUE HUI ZA ZHI., vol. 37, no. 2, 1996, pages 115 - 21
   LIN ET AL., BIOCHEM BIOPHYS RES COMMUN, vol. 208, no. 2, 17 December 1994 (1994-12-17), pages 886 - 93
   NEW ET AL., PEDIATR NEUROL., vol. 29, no. 4, 2003, pages 284 - 7
   KROOS ET AL., NEUROMUSCUL DISORD., vol. 14, no. 6, 2004, pages 371 - 4
   FERNANDEZ-HOJAS ET AL., NEUROMUSCUL DISORD., vol. 12, no. 2, 2002, pages 159 - 66
   KROOS ET AL., CLIN GENET., vol. 53, no. 5, 1998, pages 379 - 82
   HUIE ET AL., BIOCHEM BIOPHYS RES COMMUN., vol. 244, no. 3, 27 December 1996 (1996-12-27), pages 921 - 7
   HERMANS ET AL., HUM MOL GENET., vol. 3, 1994, pages 2213 - 8
   HUIE ET AL., HUM MOL GENET., vol. 3, no. 7, 1994, pages 1081 - 7
   HERMANS ET AL., HUM MUTAT., vol. 2, no. 4, 1993, pages 268 - 73
   ZHONG ET AL., AM J HUM GENET., vol. 49, no. 3, 1991, pages 635 - 45
   HERMANS ET AL., BIOCHEM BIOPHVS RES COMMUN., vol. 179, no. 2, 1991, pages 919 - 26
   RABEN ET AL., HUM MUTAT., vol. 13, no. 1, 1999, pages 83 - 4
   E.W. MARTIN: "Remington's Pharmaceutical Sciences, 18th Edition", MACK PUBLISHING
   ARAI M ET AL., CIRCULATION, vol. 97, no. 13, 7 April 1998 (1998-04-07), pages 1290 - 7
   SAWLCAR AR ET AL., PROC NATL ACAD SCI USA., vol. 99, no. 24, 26 December 2001 (2001-12-26), pages 15428 - 33
   DRENT ET AL., DIABETES NUTR METAB., vol. 15, no. 3, 2002, pages 152 - 9
   DE LUIS ROMAN DA, REV CLIN ESP., vol. 204, no. 1, January 2004 (2004-01-01), pages 32 - 4
   BERNOTAS RC ET AL., BIOCHEM J, vol. 270, no. 2, 1 September 1990 (1990-09-01), pages 539 - 40
   BOLS ET AL., JOURNAL OF CARBOHYDRATE CHEMISTRY, vol. 23, no. 4, 2004, pages 223 - 238
   SAWKER ET AL., CHEMISTRY AND BIOLOGY, vol. 12, 2005, pages 1235 - 1244
   OVERKLEEF, JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 41, 2005, pages 26522 - 26527
   TAN ET AL., JOURNAL OF BILOGICAL CHEMISTRY, vol. 266, no. 22, 1991, pages 14504 - 14510
   ROMANIOUK ET AL., GLYCOBIOLOGY, vol. 14, no. 4, 2004, pages 301 - 310
   LESUR, BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, vol. 7, no. 3, 1997, pages 355 - 360
   YOSHILCUNI, AGRIC. BIOL. CHEM, vol. 52, no. 1, 1998, pages 121
   ANZEVENO ET AL., J ORG. CHEM., vol. 54, no. 11, 1989, pages 2539
   BOSHAGEN ET AL., ANGEWANTE CHEMIE, INT. ED. ENGL., vol. 20, no. 9, 1981, pages 806 - 807
   DAVIS: "Angewante Chemie", INT. ED. ENGL., vol. 42, 2003, pages 3788 - 3792
   PERRINE ET AL., JORG. CHEM., vol. 32, 1967, pages 664
   MATOS; LOPES; LOPES, SYNTHESIS, vol. 4, 1999, pages 571
   RAO; PERLIN, CAN. J CHEM., vol. 59, 1981, pages 333
   HOOS; NAUGHTON; VASSELLA, HELV. CHIM. ACTA, vol. 76, 1993, pages 1802
   BAXTER; REITZ, J ORG. CHEM., vol. 59, 1994, pages 3175
   KINAST; SCHEDEL, ANGEW. CHEM. INT. ED. ENGL., vol. 20, 1981, pages 805
   "Current Protocols in Cell Biology", 2001, JOHN WILEY & SONS
   WATSON ET AL., ADV DRUG DELIV REV, vol. 57, no. 1, 2005, pages 43 - 61
   MIYASHITA ET AL., METHODS MOL BIOL., vol. 261, 2004, pages 399 - 410
   VUKOJEVIC ET AL., CELL MOL LIFE SCI, vol. 62, no. 5, 2005, pages 535 - 50
   CHERRY ET AL., BIOCHEM SOC TRANS, vol. 31, 2003, pages 1028 - 31
   HARIGUCHI, CELL STRUCT FUNCT, vol. 27, no. 5, 2002, pages 333 - 4
   PERIASAMY, JBIOMED OPT, vol. 6, no. 3, 2001, pages 287 - 91
   OKUMIYA ET AL., MOL GENET METAB., vol. 88, no. 1, May 2006 (2006-05-01), pages 22 - 8
   LOANNU ET AL., M. J HUM. GENET., vol. 68, 2001, pages 14 - 25
   KLINGE ET AL., NEUROMUSCUL DISORD., vol. 15, no. 1, 2005, pages 24 - 31
   VAN DEN HOUT ET AL., J INHERIT METAB DIS., vol. 24, no. 2, 2001, pages 266 - 74
   AMALFITANO ET AL., GENET MED., vol. 3, no. 2, 2001, pages 132 - 8
   VAN DEN HOUT ET AL., LANCET, vol. 56, 2000, pages 397 - 8
   VAN DEN HOUT ET AL., PEDIATRICS, vol. 113, 2004, pages 448 - 57
   WINLCEL ET AL., ANN NEUROL., vol. 55, 2004, pages 495 - 502
   SUN ET AL., MOL THER., vol. 11, no. 1, 2005, pages 57 - 65
   GOLDSPIEL ET AL., CLINICAL PHARMACY, vol. 12, 1993, pages 488 - 505
   WU; WU, BIOTHERAPY, vol. 3, 1991, pages 87 - 95
   TOLSTOSHEV, ANN. REV. PHARMACOL. TOXICOL., vol. 32, 1993, pages 573 - 596
   MULLIGAN, SCIENCE, vol. 260, 1993, pages 926 - 932
   MORGAN; ANDERSON, ANN. REV. BIOCHEM., vol. 62, 1993, pages 191 - 217
   MAY, TIBTECH, vol. 11, 1993, pages 155 - 215
   AUSUBEL ET AL.,: "Current Protocols in Molecular Biology", 1993, JOHN WILEY & SONS
   KRIEGLER: "Gene Transfer and Expression, A Laboratory Manual", 1990, STOCKTON PRESS
   DRACOPOLI ET AL.,: "Current Protocols in Human Genetics", 1994, JOHN WILEY & SONS, article "Chapters 12 and 13,"
   COLOSIMO ET AL., BIOTECHNIQUES, vol. 29, no. 2, 2000, pages 314 - 8,320-2,324
   SAMBROOK; FRITSCH; MANIATIS: "Molecular Cloning: A Laboratory Manual, Second Edition", 1989, COLD SPRING HARBOR LABORATORY PRESS
   D.N. GLOVER: "DNA Cloning: A Practical Approach", vol. I, II, 1985
   M.J. GAIT: "Oligonucleotide Synthesis", 1984
   B.D. HAMES & S.J.EHIGGINS: "Nucleic Acid Hybridization", 1985
   B.D. HAMES & S.J. HIGGINS: "Transcription And Translation", 1984
   R.I. FRESHNEY,: "Animal Cell Culture", 1986
   "Immobilized Cells And Enzymes", 1986, IRL PRESS
   B.E PERBAL: "A Practical Guide To Molecular Cloning", 1984
   MCCONNELL ET AL., HUM GENE THER., vol. 15, no. 11, 2004, pages 1022 - 33
   MCCARTY ET AL., ANNU REV GENET., vol. 38, 2004, pages 819 - 45
   MAH ET AL., CLIN. PHARMACOKINET, vol. 41, no. 12, 2002, pages 901 - 11
   SCOTT ET AL., NEUROMUSCU . DISORD., vol. 12, 2002, pages 23 - 9
   BECK ET AL., CURR GENE THER., vol. 4, no. 4, 2004, pages 457 - 67
   KOLLER; SMITHIES, PROC. NATL. ACAD. SCI. USA., vol. 86, 1989, pages 8932 - 8935
   ZIJLSTRA ET AL., NATURE, vol. 342, 1989, pages 435 - 438
   J BIOL. CHEM., vol. 62, 1987, pages 4429 - 4432
   MI ET AL., MOL. THERAPY., vol. 2, 2000, pages 339 - 47
   SCHERER ET AL., GENE THERAPY, vol. 9, 2002, pages 102 - 9
   FELGNER; RINGOLD, NATURE, vol. 337, 1989, pages 387
   BRIGHAM, AM. J MED. SCI., vol. 298, 1989, pages 278
   OSAKA ET AL., J PHARM. SCI., vol. 85, no. 6, 1996, pages 612 - 618
   SAN ET AL., HUMAN GENE THERAPY, vol. 4, 1993, pages 781 - 788
   SENIOR ET AL., BIOCHEMICA ET BIOPHYSICA ACTA., vol. 1070, 1991, pages 173 - 179
   KABANOV; KABANOV, BIOCONJUGATE CHEM., vol. 6, 1995, pages 7 - 20
   LIU ET AL., PHARMACEUT. RES., 1996, pages 13
   REMY ET AL., BIOCONJUGATE CHEN ., vol. 5, 1994, pages 647 - 654
   BEHR, J-P., BIOCONJUGATE CHEM., vol. 5, 1994, pages 382 - 389
   WYMAN ET AL., BIOCHEM., vol. 36, 1997, pages 3008 - 3017
   PFUTZNER ET AL., EXPERT OPIN. INVESTIG. DRUGS., vol. 9, 2000, pages 2069 - 83
   BOSHAGEN; GEIGER; JUNGE, ANGEWANTE CHEMIE, INT. ED. ENGL., vol. 20, no. 9, 1981, pages 806 - 807
   HALLIOGLO ET AL., PEDIATR INT., vol. 43, no. 4, 2001, pages 400 - 4
   PIPER ET AL.: "Motor Assessment of the Developing Infant", 1994, W.B. SAUNDERS CO.
   BAYLEY ET AL.: "Bayley Scores of Infant Development. 2nd Ed", 1993, HARCOURT BRACE & CO.
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.